Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Purpose: Roflumilast (Daliresp, Daxas) is a FDA-approved phosphodiesterase 4 (PDE4) inhibitor for the treatment of moderate-to-severe chronic obstructive pulmonary disease. In mice and in limited human studies, this oral medication can cause weight loss and improve insulin sensitivity. We set out to determine the mechanism of its effect on insulin sensitivity. Patients and methods: Eight adults with overweight/obesity and prediabetes received roflumilast for 6 weeks. Before and after roflumilast, subjects underwent tests of insulin sensitivity, mixed meal test, body composition, markers of inflammation, and mitochondria function. Dietary intake and physical activity were also assessed. Our primary outcome was the change in peripheral insulin sensitivity, as assessed by the hyper-insulinemic euglycemic clamp. Results: This study was underpowered for the primary outcome. Pre- and post-roflumilast mean peripheral insulin sensitivity were 48.7 and 70.0 mg/g fat free mass/minute, respectively, ( P -value=0.18), respectively. Among the mixed meal variables, roflumilast altered glucagon-like peptide 1 (GLP-1) hormone the most, although the average effect was not statistically significant ( P =0.18). Roflumilast induced a trend toward significance in 1) decreased energy intake (from 11,095 KJ to 8,4555 KJ, P =0.07), 2) decreased fat mass (from 34.53 to 32.97 kg, P =0.06), 3) decreased total and LDL cholesterol ( P =0.06 for both variables), and 4) increased plasma free fatty acids (from 0.40 to 0.50 mEq/L, P =0.09) The interval changes in adiposity and free fatty acid were significantly associated with the subject’s age ( P -value range=<0.001 to 0.02 for the correlations). Inflammatory and adhesion markers, though unchanged, significantly correlated with one another and with incretin hormones only after roflumilast. Conclusion: We demonstrate, for the first time in humans, increasing percentage of fat mass loss from roflumilast with increasing age in adults with prediabetes and overweight/obesity. We also demonstrate novel associations among roflumilast-induced changes in incretin hormones, inflammatory markers, peripheral insulin sensitivity, and adiposity. We conclude that roflumilast’s early effects on insulin sensitivity is indirect and likely mediated through roflumilast’s prioritization of lipid over glucose handling. Clinical trials registration: NCT01862029. Keywords: phosphodiesterase 4, obesity, diabetes, inflammation, incretins, aging
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Roflumilast is approved for treatment of chronic obstructive pulmonary disease and may reduce body weight and increase insulin sensitivity [184].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586
A new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544
Reactive oxygen species have a causal role in multiple forms of insulin resistance
Houstis, N., Rosen, E. D., & Lander, E. S. (2006) · Nature · doi:10.1038/nature04634 · Cited by 2,525
Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years Old
Adams, K. F., Schatzkin, A., Harris, T. B., Kipnis, V., Mouw, T., Ballard-Barbash, R., Hollenbeck, A., & Leitzmann, M. F. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055643 · Cited by 2,116
Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,349
Self-citationMacrophages, Immunity, and Metabolic Disease
McNelis, J. C., & Olefsky, J. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.010 · Cited by 720
Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
AMPK at the Nexus of Energetics and Aging
Burkewitz, K., Zhang, Y., & Mair, W. B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.002 · Cited by 483
Research works printed but not linked: 3
- [32]First MB Spitzer RL Gibbon M Williams JBW Structured Clinical Interview for DSM-IV Axis 1Disorders Washington, DC, USA American Psychiatric Press, Inc 1996
- [35]Institute of Medicine Dietary Reference Intakes: The Essential Guide to Nutrient Requirements Washington, DC The National Academies Press 2006
- [64]Burkewitz K Zhang Y Mair WB AMPK at the nexus of energetics and aging Cell Metab 2014 20 1 10 25 24726383 PMC4287273
Cited by
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Lugnier, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810616 · Cited by 53
“Interestingly, a recent review on PDE4 inhibitors in diabetic nephropathy highlights this project [95] as well as a review on PDE4 inhibitors in prediabetic patients [96].”
BackgroundPhosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
Mokrá, D., & Mokrý, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041929 · Cited by 50
“With regard to worse outcome and higher mortality of COVID-19 in older patients with diabetes mellitus or cardiovascular disorders, PDE4 inhibitors possess an advantage as they are able to increase a PDE4 activity in elderly, to reduce a body weight, to improve an insulin sensitivity [219], and to prevent adverse card…”
BackgroundRoflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
Xu, W., Zhang, J., & Xiao, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.662451 · Cited by 20
“The regulatory scope of Roflumilast covers several glucose control hormones, inflammatory markers, peripheral insulin sensitivity, and adiposity (27).”
BackgroundGomaa, A. A., Farghaly, H. S. M., Ahmed, A. M., & Hemida, F. K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109927 · Cited by 18
Metadata
- Authors
- Muo, I. M., MacDonald, S. D., Madan, R., Park, S.-J., Gharib, A. M., Martinez, P. E., Walter, M. F., Yang, S. B., Rodante, J. A., Courville, A. B., Walter, P. J., Cai, H., Glicksman, M., Guerrieri, G. M., Ben-Dor, R. R., Ouwerkerk, R., Mao, S., & Chung, J. H.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Muo, Ijeoma M
- Chung, Jay H
- ORCID
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-05
- Volume
- Volume 12
- Pages
- 743-759
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC6542328
- OpenAlex
- W2945096555
- Cited by
- 21
- References
- 65
- Citations by year
- 2025: 6 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Medical College of Wisconsin
- Endocrine Fellows Foundation
- National Institutes of Health
- National Institute of Mental Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Child Health and Human Development
- NIH Clinical Center
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- prediabetes, obesity, insulin sensitivity, phosphodiesterase-4 inhibitors, fat loss, glucagon-like peptide-1, energy intake, free fatty acids, cholesterol, inflammation, mitochondrial function, incretins, weight loss, mixed meal tolerance test, hyperinsulinemic-euglycemic clamp, body composition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study. https://app.cochat.ai/papers/10.2147/dmso.s182953
- The paper
- Muo, I. M., MacDonald, S. D., Madan, R., Park, S.-J., Gharib, A. M., Martinez, P. E., Walter, M. F., Yang, S. B., Rodante, J. A., Courville, A. B., Walter, P. J., Cai, H., Glicksman, M., Guerrieri, G. M., Ben-Dor, R. R., Ouwerkerk, R., Mao, S., & Chung, J. H. (2019). Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. https://doi.org/10.2147/dmso.s182953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.